Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atirmociclib - Pfizer

Next Previous
Drug Profile

Atirmociclib - Pfizer

Alternative Names: PF-07220060

Latest Information Update: 30 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Amines; Antineoplastics; Benzimidazoles; Cyclic ethers; Halogenated hydrocarbons; Propanols; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HER2 negative breast cancer
  • Phase II Breast cancer; Solid tumours
  • Phase I Prostate cancer

Most Recent Events

  • 28 Sep 2026 Pfizer plans a phase III FOURLIGHT-4 trial for HER2-negative-breast-cancer (Adjuvant therapy, Early stage disease) (PO) in December 2026 (NCT07890597)
  • 13 Aug 2026 Pfizer completes a phase I trial (In volunteers) in USA (PO, Tablet) (NCT07215078)
  • 09 Jul 2026 Pfizer plans a phase-I pharmacokinetics trial in USA (PO) (NCT07677358)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top